Treatment of Inflammatory Bowel Disease with Biologics
174 quantitative computed tomography scans in cohort of 74 patients (aged 5–21) initi- ating anti-TNF therapy [ 55 ]. Trabecular ...
175 studies have shown immunologic response to vaccines while on immunosuppres- sive medications, including anti-TNF therapy, al ...
176 30.9% obtained records at the time of diagnosis, a time where there may be opportunities and strategies available for catch- ...
177 observed in thiopurine-exposed patients, adding to the growing evidence that this class of medications may be the main risk ...
178 preferred anti-integrin for pediatric IBD patients who have failed anti-TNF therapy. Thus far there have been two published ...
179 successfully tapered off corticosteroids and maintained on ustekinumab therapy. More data is needed to determine the safety ...
180 de Ridder L, Rings EH, Damen GM, et al. Infliximab dependency in pediatric Crohn’s disease: long-term follow-up of an unsel ...
181 Fumery M, Jacob A, Sarter H, et al. Efficacy and safety of adalimumab after infliximab failure in pediatric Crohn disease. ...
182 Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Cr ...
183 Singh N, Rabizadeh S, Jossen J, et al. Multi-center experience of vedolizumab effectiveness in pediatric inflammatory bowel ...
© Springer International Publishing AG 2018 185 A.S. Cheifetz, J.D. Feuerstein (eds.), Treatment of Inflammatory Bowel Disease w ...
186 SIR Standardized incidence ratio TNF Tumor necrosis factor TOUCH Tysabri Outreach: Unified Commitment to Health TREAT [Crohn ...
187 including opportunistic infections. Lowered host resistance may not only influence the development of infection but may also ...
188 A recent systematic review and meta-analysis (including 49 randomized placebo- controlled studies with 14,590 participants) ...
189 anti-TNF users within the first 3 months of treatment compared to anti-TNF nonus- ers, followed by a subsequent risk decline ...
190 A pooled analysis showed that the incidence rate for serious infectious complica- tions was higher in short-term studies of ...
191 Natalizumab Natalizumab, a humanized monoclonal antibody against alpha-4 integrin, received initial FDA approval for use in ...
192 Interleukin 12/23 Monoclonal Antibody Ustekinumab Safety data of ustekinumab for induction of remission in Crohn’s disease i ...
193 Host Factor of Age: Infection Risks in Pediatric and Elderly Populations Older age appears to increase the risk of infectiou ...
194 Specific Infection Risk with Biologic Therapy Mycobacterial Infections and Invasive Fungal Infections Pathogen exposure and ...
«
5
6
7
8
9
10
11
12
13
14
»
Free download pdf